Beam Therapeutics Inc. (BEAM) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
BEAM Revenue Analysis (2017–2025)
As of March 1, 2026, Beam Therapeutics Inc. (BEAM) generated trailing twelve-month (TTM) revenue of $139.7 million, reflecting explosive growth of +279.5% year-over-year. The most recent quarter (Q4 2025) recorded $114.1 million in revenue, up 1076.6% sequentially.
Looking at the longer-term picture, BEAM's 5-year compound annual growth rate (CAGR) stands at +466.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $377.7 million in 2023.
When compared to Healthcare sector peers including ALNY (+65.2% YoY), IONS (+33.8% YoY), and ARWR (+4081.8% YoY), BEAM has underperformed the peer group in terms of revenue growth. Compare BEAM vs ALNY →
Peer Comparison
Compare BEAM's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BEAMCurrent | $140M | +279.5% | +466.3% | -274.6% | |
| ALNY | $3.7B | +65.2% | +49.8% | 13.5% | |
| IONS | $944M | +33.8% | +5.3% | -40.5% | |
| ARWR | $829M | +4081.8% | +56.6% | 11.9% | |
| CRSP | $4M | -81.7% | +37.3% | -18933.6% | |
| WVE | $108M | +103.7% | +46.6% | -101.9% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $139.7M | +120.0% | $117.4M | 84.0% | $-383,693,000 | -274.6% |
| 2024 | $63.5M | -83.2% | $-304,043,000 | -478.7% | $-415,568,000 | -654.3% |
| 2023 | $377.7M | +520.0% | $377.7M | 100.0% | $-176,485,000 | -46.7% |
| 2022 | $60.9M | +17.5% | $-250,674,000 | -411.5% | $-338,479,000 | -555.6% |
| 2021 | $51.8M | +215916.7% | $-180,290,000 | -347.8% | $-392,465,000 | -757.0% |
| 2020 | $24K | +33.3% | $-103,155,000 | -429812.5% | $-132,759,999 | -553166.7% |
| 2019 | $18K | - | $-54,601,000 | -303338.9% | $-75,154,000 | -417522.2% |
| 2018 | $0 | - | $-33,873,000 | - | $-45,741,000 | - |
| 2017 | $0 | - | $0 | - | $-8,596,363 | - |
See BEAM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BEAM Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare BEAM vs AGIO
See how BEAM stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is BEAM's revenue growth accelerating or slowing?
BEAM revenue is accelerating at +279.5% year-over-year, exceeding the 5-year CAGR of +466.3%. TTM revenue reached $140M. Growth momentum has increased versus prior periods.
What is BEAM's long-term revenue growth rate?
Beam Therapeutics Inc.'s 5-year revenue CAGR of +466.3% reflects the sustained expansion pattern. Current YoY growth of +279.5% is above this long-term average.
How is BEAM's revenue distributed by segment?
BEAM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.